Lead sponsor
Pfizer
46 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 6, 2026.
46
Trials led
9
Ongoing
10,660
Total enrollment
504
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 1
34
Phase 1/2
1
Phase 2
8
Phase 3
3
Trials by status
Recruiting
7
Active, not recruiting
2
Completed
31
Terminated
6
Trials led
TrialEligibility highlightPhaseStatusEnrollment
A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)BMI ≥27Ph 3Recruiting999
A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or ObesityBMI 27-30Ph 3Recruiting954
Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With ObesityBMI ≥23Ph 2Terminated902
A Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With ObesityBMI ≥30Ph 2Completed628
A 16 Week Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Type 2 Diabetes MellitusBMI 24.5-45.4Ph 2Completed412
A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without DiabetesBMI 27-38Ph 1/2Recruiting381
4-Week, Multiple-dose, Dose-escalating Study In Patients With Type 2 DiabetesHbA1c 7-10.5%Ph 1Completed98
A Study to Learn How the Study Medicine Danuglipron is Taken Up Into the Blood and If Danuglipron Changes How the Body Processes Other Study Medicines (Atorvastatin and Rosuvastatin) in Healthy Adults Who Are Overweight or ObeseBMI 25-45.4Ph 1Completed82
Multiple Escalating Oral Doses Study of PF-07081532 in Adult Participants With Type 2 Diabetes MellitusHbA1c 7-10.5%Ph 1Completed66
Methodology Study To Examine 6-Week Food Intake With Liraglutide In Obese SubjectsBMI 30-40Ph 1Completed61
A Study to Learn How the Study Medicine Called PF-08653944 is Taken up Into the Blood in Adults With Overweight or ObesityBMI 27-45Ph 1Active, not recruiting54
STUDY OF PF-06882961 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WITH VARYING DEGREES OF RENAL IMPAIRMENT AND PARTICIPANTS WITHOUT RENAL IMPAIRMENTBMI 18-45.4Ph 1Completed42
Multiple Dose Escalation Trial Of PF-04603629 Given To Subjects With Type 2 Diabetes MellitusBMI 22-40Ph 1Terminated42
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06882961 in Japanese Adults With Type 2 Diabetes MellitusBMI 22.5-45.4Ph 1Completed37
STUDY TO EVALUATE THE EFFECT OF PF-06882961 ON SINGLE DOSE ATORVASTATIN, MEDAZOLAM AND ORALCONTRACEPTIVE PHARMACOKINETICS IN HEALTHY ADULT PARTICIPANTSBMI 20-30Ph 1Completed35
Study of Multiple Oral Doses of PF-07081532 in Adult Participants With Type 2 Diabetes MellitusBMI 24.5-45.5Ph 1Completed34
Study to Learn How Different Forms of The Study Medicine Called Danuglipron Are Taken up Into the Blood In Healthy AdultsBMI 16-32Ph 1Completed33
STUDY TO COMPARE PHARMACOKINETICS (PK) OF SINGLE ORAL DOSES OF DIFFERENT PF-06882961 FORMULATIONS IN PARTICIPANTS WHO ARE OVERWEIGHT OR HAVE OBESITYBMI 25-40Ph 1Completed31
A Drug-Drug Interaction Study Between PF-06882961 and PF-06865571 in Healthy Adult Participants and Overweight Adults or Adults With Obesity Who Are Otherwise HealthyHealthy volunteersPh 1Completed27
A Study to Learn About the Medicine Called PF-08653944 in People With and Without Reduced Liver FunctionBMI ≥21Ph 1Recruiting26
First In Human, Single Escalating Oral Dose Study Of PF-06882961 In Healthy Adult SubjectsBMI 17.5-30.5Ph 1Completed25
STUDY OF PF-06882961 IN PARTICIPANTS WITH AND WITHOUT VARYING DEGREES OF HEPATIC IMPAIREMENTBMI 17.5-38Ph 1Completed24
A Study to Understand How the Study Medicine (PF-07081532) is Processed in People With Liver DysfunctionBMI 17.5-38Ph 1Completed24
A Study to Learn How Different Amounts of the Study Medicine Danuglipron Are Taken up Into the Blood in Otherwise Healthy Adults With Overweight or ObesityBMI 25-45.4Ph 1Completed23
Study of Single Ascending Doses of PF-07081532 in Healthy Adult ParticipantsBMI 17.5-30.5Ph 1Completed22
A Study to Learn About the Effect of Study Medicine Called PF-08653944 on How Quickly the Stomach Empties Its Content in Healthy Adults With Overweight or ObesityBMI 27-45Ph 1Recruiting20
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of PF-06882961 in Chinese Adults With Type 2 Diabetes MellitusBMI 22.5-45.4Ph 1Completed20
A Study to Compare Two Different Forms of PF-07081532 in Adults Who Are Overweight or ObeseBMI 25-34.9Ph 1Completed20
A Clinical Trial of the Study Medicine (PF-07081532) in People With Diabetes and Kidney DysfunctionBMI 17.5-45.4Ph 1Terminated18
Study To Evaluate The Effect Of Two Steady State Doses of PF 06882961 On Rosuvastatin And Midazolam Pharmacokinetics In Otherwise Healthy Adult Participants With ObesityBMI ≥30Ph 1Completed16
A Drug-Drug Interaction Study to Examine the Impact of Itraconazole and Cyclosporine on PF-07081532 Pharmacokinetics in Overweight or Obese AdultsBMI ≥25Ph 1Completed16
A Drug-Drug Interaction Study to Estimate the Effect of PF-07081532 on the Pharmacokinetics of Dabigatran and Rosuvastatin in Overweight or Obese Adult ParticipantsBMI ≥25Ph 1Terminated16
A Study to Learn if the Study Medicines Called Itraconazole and Cyclosporine Change How the Body Processes the Other Study Medicine Called Danuglipron in Healthy Adults.BMI 16-32Ph 1Completed16
A Single Dose Crossover Study In Healthy Subjects To Evaluate Different Formulations Of PF-06882961BMI 17.5-30.5Ph 1Completed12
A Study to Understand How the Study Medicine (PF-07081532) is Processed and Eliminated in Healthy MenBMI 17.5-30.5Ph 1Completed6